{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:30:31Z","timestamp":1791117031782,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T00:00:00Z","timestamp":1329436800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10557-012-6373-5","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T01:45:09Z","timestamp":1329356709000},"page":"181-187","source":"Crossref","is-referenced-by-count":81,"title":["ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies"],"prefix":"10.1007","volume":"26","author":[{"given":"Stephen J.","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Johannson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Barter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bryan","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman C.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn R. N.","family":"Borgman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,17]]},"reference":[{"key":"6373_CR1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"6373_CR2","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"F Turnbull","year":"2003","unstructured":"Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527\u201335.","journal-title":"Lancet"},{"key":"6373_CR3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","volume":"62","author":"T Gordon","year":"1977","unstructured":"Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707\u201314.","journal-title":"Am J Med"},{"key":"6373_CR4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","volume":"357","author":"P Barter","year":"2007","unstructured":"Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301\u201310.","journal-title":"N Engl J Med"},{"key":"6373_CR5","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","volume":"85","author":"JJ Badimon","year":"1990","unstructured":"Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234\u201341.","journal-title":"J Clin Invest"},{"key":"6373_CR6","first-page":"455","volume":"60","author":"JJ Badimon","year":"1989","unstructured":"Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest. 1989;60:455\u201361.","journal-title":"Lab Invest"},{"key":"6373_CR7","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1161\/01.ATV.0000184760.95957.d6","volume":"25","author":"SJ Nicholls","year":"2005","unstructured":"Nicholls SJ, Cutri B, Worthley SG, Kee P, Rye KA, Bao S, Barter PJ. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 2005;25:2416\u201321.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6373_CR8","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1073\/pnas.91.20.9607","volume":"91","author":"AS Plump","year":"1994","unstructured":"Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Nat Acad Sci (USA). 1994;91:9607\u201311.","journal-title":"Proc Nat Acad Sci (USA)"},{"key":"6373_CR9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","volume":"353","author":"EM Rubin","year":"1991","unstructured":"Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265\u20137.","journal-title":"Nature"},{"key":"6373_CR10","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1161\/hc4501.098952","volume":"104","author":"JX Rong","year":"2001","unstructured":"Rong JX, Li J, Reis ED, Choudhury RP, Dansky HM, Elmalem VI, Fallon JT, Breslow JL, Fisher EA. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation. 2001;104:2447\u201352.","journal-title":"Circulation"},{"key":"6373_CR11","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1161\/hc2501.092494","volume":"103","author":"PK Shah","year":"2001","unstructured":"Shah PK, Yano J, Reyes O, Chyu K-Y, Kaul S, Bisgaier CL, Drake S, Cercek B. High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Circulation. 2001;103:3047\u201350.","journal-title":"Circulation"},{"key":"6373_CR12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/BF02938393","volume":"9","author":"HB Brewer Jr","year":"2007","unstructured":"Brewer Jr HB. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr Cardiol Rep. 2007;9:486\u201392.","journal-title":"Curr Cardiol Rep"},{"key":"6373_CR13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.RES.0000146094.59640.13","volume":"95","author":"PJ Barter","year":"2004","unstructured":"Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95:764\u201372.","journal-title":"Circ Res"},{"key":"6373_CR14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa020194","volume":"347","author":"WE Kraus","year":"2002","unstructured":"Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347:1483\u201392.","journal-title":"N Engl J Med"},{"key":"6373_CR15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","volume":"297","author":"SJ Nicholls","year":"2007","unstructured":"Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499\u2013508.","journal-title":"JAMA"},{"key":"6373_CR16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjcard.2009.05.020","volume":"104","author":"Y Cui","year":"2009","unstructured":"Cui Y, Watson DJ, Girman CJ, Shapiro DR, Gotto AM, Hiserote P, Clearfield MB. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force\/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol. 2009;104:829\u201334.","journal-title":"Am J Cardiol"},{"key":"6373_CR17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1185\/030079904125003421","volume":"20","author":"VG Athyros","year":"2004","unstructured":"Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Mercouris BR, Pehlivanidis A, Bouloukos VI, Elisaf M. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin. 2004;20:627\u201337.","journal-title":"Curr Med Res Opin"},{"key":"6373_CR18","doi-asserted-by":"crossref","unstructured":"Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet;375:1875\u20131884.","DOI":"10.1016\/S0140-6736(10)60656-3"},{"key":"6373_CR19","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","volume":"8","author":"PL Canner","year":"1986","unstructured":"Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"6373_CR20","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","volume":"345","author":"BG Brown","year":"2001","unstructured":"Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583\u201392.","journal-title":"N Engl J Med"},{"key":"6373_CR21","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","volume":"110","author":"AJ Taylor","year":"2004","unstructured":"Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512\u20137.","journal-title":"Circulation"},{"key":"6373_CR22","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","volume":"361","author":"AJ Taylor","year":"2009","unstructured":"Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113\u201322.","journal-title":"N Engl J Med"},{"key":"6373_CR23","unstructured":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011."},{"key":"6373_CR24","doi-asserted-by":"crossref","first-page":"58B","DOI":"10.1016\/j.amjcard.2008.02.039","volume":"101","author":"BG Brown","year":"2008","unstructured":"Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol. 2008;101:58B\u201362B.","journal-title":"Am J Cardiol"},{"key":"6373_CR25","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","volume":"290","author":"SE Nissen","year":"2003","unstructured":"Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292\u2013300.","journal-title":"JAMA"},{"key":"6373_CR26","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","volume":"297","author":"JC Tardif","year":"2007","unstructured":"Tardif JC, Gregoire J, L\u2019Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675\u201382.","journal-title":"JAMA"},{"key":"6373_CR27","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.jacc.2009.12.067","volume":"55","author":"R Waksman","year":"2010","unstructured":"Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, Martin BD, Perlman TJ, Maltais JA, Weissman NJ, Fitzgerald PJ, Brewer Jr HB. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55:2727\u201335.","journal-title":"J Am Coll Cardiol"},{"key":"6373_CR28","first-page":"950","volume":"9","author":"SJ Nicholls","year":"2008","unstructured":"Nicholls SJ. HDL: still a target for new therapies? Curr Opin Investig Drugs. 2008;9:950\u20136.","journal-title":"Curr Opin Investig Drugs"},{"key":"6373_CR29","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304\u201316.","journal-title":"N Engl J Med"},{"key":"6373_CR30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","volume":"370","author":"ML Bots","year":"2007","unstructured":"Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153\u201360.","journal-title":"Lancet"},{"key":"6373_CR31","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","volume":"356","author":"JJ Kastelein","year":"2007","unstructured":"Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620\u201330.","journal-title":"N Engl J Med"},{"key":"6373_CR32","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109\u201322.","journal-title":"N Engl J Med"},{"key":"6373_CR33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.ATV.0000256728.60226.77","volume":"27","author":"AR Tall","year":"2007","unstructured":"Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27:257\u201360.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6373_CR34","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","volume":"118","author":"SJ Nicholls","year":"2008","unstructured":"Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118:2506\u201314.","journal-title":"Circulation"},{"key":"6373_CR35","doi-asserted-by":"crossref","first-page":"32E","DOI":"10.1016\/j.amjcard.2009.09.017","volume":"104","author":"M Vergeer","year":"2009","unstructured":"Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol. 2009;104:32E\u20138E.","journal-title":"Am J Cardiol"},{"key":"6373_CR36","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ahj.2009.09.017","volume":"158","author":"GG Schwartz","year":"2009","unstructured":"Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158:896\u2013901 e893.","journal-title":"Am Heart J"},{"key":"6373_CR37","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","volume":"306","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306:2099\u2013109.","journal-title":"JAMA"},{"key":"6373_CR38","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","volume":"363","author":"CP Cannon","year":"2010","unstructured":"Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406\u201315.","journal-title":"N Engl J Med"},{"key":"6373_CR39","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.jacc.2010.02.035","volume":"55","author":"D Bailey","year":"2010","unstructured":"Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J, Krimbou L, Wong NC, Genest J. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55:2580\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"6373_CR40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jacc.2010.11.015","volume":"57","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Gordon A, Johansson J, Wolski K, Ballantyne CM, Kastelein JJ, Taylor A, Borgman M, Nissen SE. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011;57:1111\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"6373_CR41","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","volume":"295","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556\u201365.","journal-title":"JAMA"},{"key":"6373_CR42","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071\u201380.","journal-title":"JAMA"},{"key":"6373_CR43","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","volume":"365","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078\u201387.","journal-title":"N Engl J Med"},{"key":"6373_CR44","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217\u201325.","journal-title":"JAMA"},{"key":"6373_CR45","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochelliere R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561\u201373.","journal-title":"JAMA"},{"key":"6373_CR46","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008;299:1547\u201360.","journal-title":"JAMA"},{"key":"6373_CR47","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa054699","volume":"354","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006;354:1253\u201363.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-012-6373-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-012-6373-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-012-6373-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T16:17:07Z","timestamp":1561306627000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-012-6373-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,17]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["6373"],"URL":"https:\/\/doi.org\/10.1007\/s10557-012-6373-5","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,17]]}}}